This talk summarizes recent QCD results from HERA, the Tevatron Collider and Tevatron fixed target experiments.

Ion beam cancer therapy (IBCT, or hadron therapy) represents an effective method for providing high-dose delivery into tumours, thereby maximizing the probability of killing the cancer cells whilst simultaneously minimizing the radiation damage to surrounding healthy tissue [2]. Despite its high cost, proton-beam therapy is widely spread around the world with over 60 operational centres [3]. Th...

The application of laser accelerated ion beams in hadron therapy requires a beam optics with unique features. Due to the spectral and spatial distribution of laser accelerated protons a compact ion optical system with therapy applications, based on Gabor space charge lenses for collecting, focusing and energy filtering the laser produced proton beam, has significant advantages compared with oth...

We review a recent global analysis of inclusive single-charged-hadron production in high-energy colliding-beam experiments, which is performed at nextto-leading order (NLO) in the parton model of quantum chromodynamics endowed with nonperturbative fragmentation functions (FFs). Comparisons of pp data from CERN SppS and the Fermilab Tevatron and γp data from DESY HERA with the corresponding NLO ...

Hadron therapy allows for highly conformal dose distributions and better sparing of organs-at-risk, thanks to the characteristic dose deposition as function of depth. However, the quality of hadron therapy treatments is closely connected with the ability to predict and achieve a given beam range in the patient. Currently, uncertainties in particle range lead to the employment of safety margins,...